Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Q BioMed in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.60.
Current Consensus is
The current consensus among 0 investment analysts is to n/a stock in Q BioMed. This rating has held steady since April 2020, when it changed from a Buy consensus rating.
Q BioMed, Inc. operates as a biomedical acceleration and development company. It focuses on acquiring and in-licensing pre-clinical, clinical-stage and approved life sciences therapeutic products. Its products include Strontium-89, MetastronTM, QBM-001, Uttroside-B, and MAN 01. The company was founded by Enrique Navas on November 22, 2013 and is headquartered in New York, NY.